LYKALABS Stock Overview
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Lyka Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹126.00 |
| 52 Week High | ₹144.30 |
| 52 Week Low | ₹88.50 |
| Beta | 1.15 |
| 1 Month Change | 16.50% |
| 3 Month Change | 2.90% |
| 1 Year Change | 21.56% |
| 3 Year Change | 220.20% |
| 5 Year Change | 349.20% |
| Change since IPO | 6.33% |
Recent News & Updates
Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely
Apr 10
Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21Recent updates
Getting In Cheap On Lyka Labs Limited (NSE:LYKALABS) Is Unlikely
Apr 10Subdued Growth No Barrier To Lyka Labs Limited's (NSE:LYKALABS) Price
Jan 05We Think Lyka Labs (NSE:LYKALABS) Has A Fair Chunk Of Debt
Nov 21These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Extensively
Jun 08A Look At The Fair Value Of Lyka Labs Limited (NSE:LYKALABS)
Mar 15Unpleasant Surprises Could Be In Store For Lyka Labs Limited's (NSE:LYKALABS) Shares
Aug 25Is Lyka Labs (NSE:LYKALABS) A Risky Investment?
Jun 11These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Feb 21Statutory Profit Doesn't Reflect How Good Lyka Labs' (NSE:LYKALABS) Earnings Are
Nov 05These 4 Measures Indicate That Lyka Labs (NSE:LYKALABS) Is Using Debt Reasonably Well
Nov 03Shareholder Returns
| LYKALABS | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.2% | 1.4% | 2.8% |
| 1Y | 21.6% | 57.2% | 46.6% |
Return vs Industry: LYKALABS underperformed the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: LYKALABS underperformed the Indian Market which returned 46.4% over the past year.
Price Volatility
| LYKALABS volatility | |
|---|---|
| LYKALABS Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: LYKALABS has not had significant price volatility in the past 3 months.
Volatility Over Time: LYKALABS's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 296 | Kunal Gandhi | www.lykalabs.com |
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data.
Lyka Labs Limited Fundamentals Summary
| LYKALABS fundamental statistics | |
|---|---|
| Market cap | ₹4.17b |
| Earnings (TTM) | -₹36.68m |
| Revenue (TTM) | ₹1.02b |
4.1x
P/S Ratio-113.7x
P/E RatioIs LYKALABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYKALABS income statement (TTM) | |
|---|---|
| Revenue | ₹1.02b |
| Cost of Revenue | ₹425.24m |
| Gross Profit | ₹594.86m |
| Other Expenses | ₹631.54m |
| Earnings | -₹36.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.11 |
| Gross Margin | 58.31% |
| Net Profit Margin | -3.60% |
| Debt/Equity Ratio | 79.2% |
How did LYKALABS perform over the long term?
See historical performance and comparison